3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Squamous Cell Carcinoma of Head and Neck
8
Neoplasms
6
Head and Neck Neoplasms
6
Prostatic Neoplasms
5
Oropharyngeal Neoplasms
5
Lung Neoplasms
5
Urinary Bladder Neoplasms
4
Stomach Neoplasms
4
Neoplasm Metastasis
4
Myasthenia Gravis
4
Lymphoma, Large B-Cell, Diffuse
4
Cholangiocarcinoma
4
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Mouth Neoplasms
3
Leukemia, Myeloid, Acute
3
Laryngeal Neoplasms
3
Hypopharyngeal Neoplasms
3
Glioblastoma
3
Fatigue
3
Endometrial Neoplasms
3
Carcinoma
3
Breast Neoplasms
3
Weight Loss
2
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Nasopharyngeal Carcinoma
2
Melanoma
2
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Camurati-Engelmann Syndrome
×
30 days
×
Clear all
NCT06788990
2026-06-02
FORTIFI-HN01
Bicara Therapeutics
Phase 2/3
Recruiting
650 enrolled